CompletedPhase 2

[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease

South Korea135 participantsStarted 2016-01-11

Plain-language summary

This is a cross-sectional and longitudinal study to evaluate the clinical utility of \[18F\]THK-5351 positron emission computed tomography in cognitively healthy volunteers, mild cognitive impairment (MCI), Alzheimer's disease (AD) and other neurodegenerative patients.

Who can participate

Age range40 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. General Subject Inclusion Criteria
✓. Cognitively Healthy Subjects
✓. MCI Subjects
✓. AD Subjects
✓. Subjects with other neurodegenerative disease

What they're measuring

Cross-sectional [18F]THK-5351 Imaging Results

Timeframe: 50-70 minutes post injection

Assess the rate of change of tau deposition as measured by [18F]THK-5351 uptake (SUVR) over time

Timeframe: 24 months

Trial details

NCT IDNCT02656498

SponsorJae Seung Kim

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12-31

View on ClinicalTrials.gov More Alzheimer's Disease trials